ADMA BIOLOGICS, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ADMA Biologics, Inc. on March 18, 2019. The filing serves to announce an upcoming investor presentation scheduled for March 19, 2019, at Oppenheimer's 29th Annual Healthcare Conference in New York, NY.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is an event notification and does not contain financial statements or performance data.
Material Changes
No material changes to financial position or operations are reported in this document. The primary event is the scheduled presentation by Adam Grossman (President and CEO) and Brian Lenz (Executive Vice President and CFO).
Guidance, Outlook, and Risks
The filing references an updated investor presentation (Exhibit 99.1) which contains forward-looking statements. The text directs readers to Exhibit 99.1 for a discussion of risks and uncertainties related to these statements. No specific guidance or outlook details are provided within the body of this 8-K.
Key Facts for Investor Verification
- Verify the content of the March 2019 Investor Presentation filed as Exhibit 99.1 for forward-looking statements and risk factors.
- Confirm the live webcast details and access via the "Investor Relations" tab on www.admabiologics.com.
- Note that this filing contains no financial data; refer to the most recent 10-K or 10-Q for financial metrics.